Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, despite recent underperformance compared to the market [2][4]. Core Insights - The cosmetics and medical beauty sector has shown weaker performance than the market, with the Shenwan Beauty Care Index declining by 4.8% from March 13 to March 20, 2026, underperforming the Shenwan A Index by 0.7 percentage points [4][5]. - Upcoming earnings reports from key companies such as Lin Qingxuan and Shangmei will be critical for assessing market trends and performance [4][9]. - Notable company performances include: - Aimei Ke reported a revenue of 2.453 billion yuan for 2025, down 18.94% year-on-year, with a net profit of 1.291 billion yuan, down 34.05% [10]. - Juzi Biotechnology's revenue was 5.519 billion yuan, a slight decrease of 0.4%, with a net profit of 1.915 billion yuan, down 7.2% [10] [11]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector is currently underperforming the market, with specific indices showing declines [4][5]. - The Shenwan Cosmetics Index fell by 3.4%, while the Shenwan Personal Care Index dropped by 4.4% [4]. Company Highlights - Aimei Ke's Q4 2025 revenue was 588 million yuan, down 9.61% year-on-year, with a net profit of 198 million yuan, down 46.85% [10]. - Juzi Biotechnology's effective skincare products generated 4.337 billion yuan in revenue, a 0.8% increase, while medical dressings saw a 4.8% decline [11]. Market Trends - The report highlights the importance of upcoming earnings disclosures from major companies, which are expected to provide insights into market recovery and performance [4][9]. - The overall retail sales of cosmetics in January-February 2026 grew by 4.5%, indicating a relative resilience in the beauty sector compared to the overall retail market [14]. E-commerce and Brand Performance - The report provides data on e-commerce performance, noting that domestic brands are gaining market share, with significant growth in GMV for brands like Shangmei [13]. - The report emphasizes the competitive landscape, with domestic brands increasingly challenging international players in market share [21][23].

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry [2] Core Insights - The cosmetics and medical beauty sector has underperformed the market recently, with the Shenwan Beauty Care Index declining by 4.8% from March 13 to March 20, 2026, which is 0.7 percentage points worse than the Shenwan A Index [4][5] - Upcoming earnings reports from key companies such as Lin Qingxuan and Shangmei will be critical to monitor [4][10] - The report highlights the performance of major companies, noting that Aimeike's revenue for 2025 is projected at 2.453 billion yuan, a year-on-year decrease of 18.94% [11] Summary by Sections Industry Performance - The Shenwan Cosmetics Index fell by 3.4%, while the Shenwan Personal Care Index dropped by 4.4%, indicating varied performance within the sector [4][5] - The report notes that the beauty care sector is entering earnings season, with several companies set to announce their financial results [10] Company Highlights - Aimeike's 2025 performance shows a revenue of 2.453 billion yuan, down 18.94% year-on-year, with a net profit of 1.291 billion yuan, down 34.05% [11] - Juzi Biotechnology reported a slight revenue decline of 0.4% to 5.519 billion yuan, with a net profit decrease of 7.2% [11] - The report emphasizes the importance of product matrix improvement and collaboration for growth in Aimeike's future performance [12] Market Trends - The report indicates that the retail sales of cosmetics in China grew by 4.5% year-on-year in the first two months of 2026, outperforming overall retail growth [16] - The report also notes that the domestic market is seeing a shift towards local brands, with significant growth in market share for domestic products [23] Industry Dynamics - The report discusses the strategic partnership between L'Oréal and NVIDIA to enhance AI research in beauty products, reflecting a trend towards technological integration in the industry [20] - The competitive landscape is evolving, with domestic brands gaining ground against international players, particularly in the skincare segment [23]

Core Viewpoint - The company reported a slight decline in revenue and net profit for 2025, indicating a challenging year impacted by external factors and market conditions [4][5]. Financial Performance - In 2025, the company achieved a revenue of 5.52 billion yuan, a year-on-year decrease of 0.4%, and a net profit attributable to shareholders of 1.91 billion yuan, down 7.2% year-on-year [4]. - The adjusted net profit was 1.96 billion yuan, reflecting an 8.9% decline year-on-year [4]. - The first half of 2025 saw revenue of 3.11 billion yuan, up 22.5% year-on-year, while the second half experienced a revenue drop to 2.41 billion yuan, down 19.8% year-on-year [4]. Product Performance - The professional skin care products generated revenue of 5.50 billion yuan, a decrease of 0.4% year-on-year, with functional skin care products contributing 4.34 billion yuan, up 0.8% [5]. - The medical dressings segment reported revenue of 1.16 billion yuan, down 4.8% year-on-year [5]. - The health food and other businesses achieved revenue of 21.7 million yuan, an increase of 17.9% year-on-year [5]. Brand Analysis - The company's main brand, 可复美, generated revenue of 4.47 billion yuan, a decline of 1.6% year-on-year, while the 可丽金 brand saw revenue growth of 9.2% to 920 million yuan [5]. - In the first half of 2025, 可复美's revenue was 2.54 billion yuan, up 22.7%, but fell to 1.93 billion yuan in the second half, down 22.0% [5]. New Product Launches - In 2025, the company launched the 可复美胶原棒 2.0 and plans to introduce significant new products in 2026 for the collagen repair series [6]. - The company also introduced the 可复美帧域密修 series, targeting skin repair needs due to external heat sources [6]. - The 可丽金 brand launched the upgraded version of its flagship product, with plans for further new releases in 2026 [6]. Sales Channel Performance - Direct-to-consumer (DTC) online sales generated 3.40 billion yuan, down 5.2% year-on-year, while e-commerce platform sales increased by 34.8% to 510 million yuan [6]. - Offline direct sales rose by 32.3% to 220 million yuan, and distribution sales decreased by 1.5% to 1.38 billion yuan [6]. Profitability and Cost Structure - The company's gross margin decreased by 1.8 percentage points to 80.3%, attributed to changes in product mix and a decline in high-margin medical dressing revenue [8]. - The sales, management, and R&D expense ratios were 37.3%, 3.1%, and 1.6%, respectively, with sales expenses increasing due to higher brand investment and declining revenue [8]. Future Growth Potential - The company plans to optimize its skincare product structure and reduce reliance on single products through new launches in 2026 [9]. - The medical aesthetics segment is expected to contribute to revenue growth with the approval of new products in 2025 and 2026 [9].

Investment Rating - The report maintains a "Buy" rating for the company, with a current price of HKD 30.70 and a fair value estimate of HKD 33.66 [4][9]. Core Insights - The company's performance is under short-term pressure, but there is optimism regarding the long-term value of its collagen products due to ongoing restructuring efforts [1][9]. - In 2025, the company reported revenue of RMB 55.2 billion, a slight decline of 0.4% year-on-year, and a net profit of RMB 19.1 billion, down 7.2% year-on-year [9][10]. - The report highlights a competitive industry landscape and changes in product structure that have led to a decrease in gross margin by 1.8 percentage points to 80.3% [9][10]. Financial Projections - Revenue is projected to grow from RMB 6.07 billion in 2026 to RMB 7.89 billion in 2028, with growth rates of 10.0%, 13.1%, and 14.9% respectively [2][10]. - The net profit is expected to increase from RMB 19.8 billion in 2026 to RMB 23.9 billion in 2028, with growth rates of 4%, 9%, and 11% respectively [10][11]. - The report anticipates a decline in overall gross margin to around 78%-79% during 2026-2028 due to a shift in product mix [10][11]. Business Segment Analysis - The efficacy skincare segment generated revenue of RMB 43.4 billion in 2025, showing a slight increase of 0.8% year-on-year, driven by enhanced marketing efforts [9][10]. - The medical beauty dressing segment saw revenue of RMB 11.6 billion, down 4.8% year-on-year, primarily due to price maintenance and channel sales control [9][10]. - Brand performance varied, with "可复美" (Kefumei) revenue declining by 1.6% to RMB 44.7 billion, while "可丽金" (Kelin) revenue increased by 9.2% to RMB 9.2 billion, benefiting from online channel expansion [9][10]. Channel Performance - Online direct-to-consumer (DTC) sales reached RMB 34.0 billion, down 5%, while e-commerce platform direct sales increased by 35% to RMB 5.1 billion [9][10]. - Offline direct sales grew by 32% to RMB 2.2 billion, supported by an increase in the number of cosmetic chain stores [9][10]. - Revenue from distributors decreased by 2% to RMB 13.8 billion due to pricing and channel management pressures [9][10]. Investment Recommendations - The company is in a critical phase of product matrix upgrade and channel structure optimization, with short-term performance adjustments expected to be absorbed [10][11]. - The report suggests that with the launch of new medical beauty products and improved online channel efficiency, the company is likely to return to a growth trajectory by 2026 [10][11].

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company has reported its 2025 annual performance, achieving revenue of 5.519 billion yuan, a year-on-year decrease of 0.4%, and a net profit attributable to shareholders of 1.915 billion yuan, down 7.2% year-on-year [2] - The company plans to distribute a total dividend of 1.2104 yuan per share, amounting to approximately 1.29 billion yuan [2] - The company is expected to return to a growth trend in 2026, driven by new product launches and improved channel structures [8] Revenue Summary - In 2025, the company's revenue was 5.519 billion yuan, with a breakdown by product category showing functional skincare products at 4.337 billion yuan (+0.8% YoY), medical dressings at 1.16 billion yuan (-4.8% YoY), and health food and others at 0.22 billion yuan (+17.9% YoY) [3] - By brand, revenue from Kefu Mei was 4.47 billion yuan (-1.6% YoY), Keli Jin at 0.918 billion yuan (+9.2% YoY), and others at 0.22 billion yuan (+17.9% YoY) [3] - Revenue by channel showed DTC online sales at 3.402 billion yuan (-5.2% YoY), e-commerce platform sales at 0.509 billion yuan (+34.8% YoY), offline sales at 0.225 billion yuan (+32.3% YoY), and distribution at 1.383 billion yuan (-1.5% YoY) [3] Profitability Summary - The company's gross margin for 2025 was 80.34%, a decrease of 1.76 percentage points year-on-year, with a net profit margin of 34.70%, down 2.52 percentage points year-on-year [4] - The company’s operating expenses ratio for 2025 was 41.92%, an increase of 1.02 percentage points year-on-year, with significant increases in sales expenses [5] Product and Channel Development - The company is focusing on product development and channel construction to drive high-quality brand growth, with plans to launch new products and expand into new markets [6][7] - The company is enhancing its online operations and expanding its offline store presence, including entry into overseas markets such as Singapore and Malaysia [7] Financial Forecast - The company forecasts revenues of 6.113 billion yuan, 6.932 billion yuan, and 7.821 billion yuan for 2026, 2027, and 2028 respectively, with net profits of 1.950 billion yuan, 2.139 billion yuan, and 2.334 billion yuan for the same years [8][10] - The expected earnings per share (EPS) for 2026, 2027, and 2028 are 1.82 yuan, 2.00 yuan, and 2.18 yuan respectively, with corresponding price-to-earnings (PE) ratios of 16, 14, and 13 [8][10]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The skincare business is expected to regain momentum in the second half of the year, while the medical aesthetics segment is building a new growth curve [1] - The company reported a revenue of 5.52 billion yuan for 2025, a slight decrease of 0.4% year-on-year, and a net profit attributable to shareholders of 1.91 billion yuan, down 7.2% year-on-year [3][4] - The first half of 2025 saw a revenue of 3.11 billion yuan, up 22.5% year-on-year, while the second half experienced a decline of 19.8% [3][4] Revenue Performance - The company's professional skincare products generated revenue of 5.50 billion yuan in 2025, with functional skincare products accounting for 4.34 billion yuan, a year-on-year increase of 0.8% [4] - The revenue from the medical dressing segment was 1.16 billion yuan, down 4.8% year-on-year [4] - The company's main brand, 可复美, generated 4.47 billion yuan in revenue, a decrease of 1.6% year-on-year, while the 可丽金 brand saw a revenue increase of 9.2% to 0.92 billion yuan [4] Product and Brand Development - In 2025, the company launched the 可复美胶原棒 2.0 and plans to introduce significant new products in 2026 [5] - The company is also focusing on expanding its product matrix with new launches in various series, which is expected to optimize revenue structure [7] Financial Metrics - The company's gross margin decreased by 1.8 percentage points to 80.3% in 2025, attributed to changes in product mix and a decline in high-margin medical dressing revenue [6] - The sales, management, and R&D expense ratios were 37.3%, 3.1%, and 1.6% respectively, with an increase in sales expense ratio due to heightened brand investment [6] Future Outlook - The company is expected to return to a growth trajectory through continuous product innovation and expansion in the medical aesthetics sector [7] - The net profit forecasts for 2026 and 2027 have been adjusted to 2.01 billion yuan and 2.37 billion yuan, respectively, reflecting a downward revision of 42% and 47% [7]

Investment Rating - The investment rating for the retail industry is "Positive" (maintained) [1] Core Insights - The report highlights the strong performance of domestic brands during the 38 promotional event, with significant sales figures and consumer demand for effective skincare products [23][25] - The report emphasizes the importance of emotional consumption themes and recommends high-quality companies in high-growth sectors [6][30][31] Summary by Sections Retail and Social Services Market Review - The retail and social services indices reported declines of 3.91% and 3.63% respectively during the week of March 2 to March 6, 2026, ranking 25th and 23rd among 31 primary industries [5][15] - Year-to-date, the retail index has decreased by 6.82%, while the social services index has increased by 3.01% [12][15] Industry Dynamics - The 38 promotional event saw domestic brands excel, with significant sales figures reported from live streaming platforms [23][25] - Key brands such as Pechoin and Betainy led in product selection and sales performance during the promotional period [23][24] Investment Recommendations - Investment focus areas include: - Gold and jewelry brands with differentiated product offerings, recommending companies like Laopuhuangjin and Chaohongji [6][30] - Offline retail companies adapting to market changes, recommending Yonghui Supermarket and Aiyingshi [6][30] - Domestic beauty brands that emphasize emotional value and innovative ingredients, recommending Maogeping and Shangmei [6][31] - Medical aesthetics firms with differentiated products, recommending Meilitiantian and Aimeike [6][31] Company Performance Highlights - Shangmei Co. is projected to achieve revenues of 9.1-9.2 billion yuan, a year-on-year increase of 34.0%-35.4%, with net profits expected to reach 1.14-1.16 billion yuan, up 41.9%-44.4% [27][29] - Zhou Dafu reported a retail value increase of 17.8% year-on-year for FY2026Q3, driven by product structure optimization [32]

Core Insights - The "Qihang·2025 Financial Summit" was successfully held in Beijing, focusing on "New Starting Point, New Momentum, New Journey," gathering hundreds of leaders and guests from regulatory bodies, industry associations, financial institutions, listed companies, and media [1] - The "Jizhi Award" was announced, with Juzhi Biotechnology winning the "Outstanding Growth Enterprise" award, aimed at setting high-quality development benchmarks and guiding listed companies to focus on their main business and continuous innovation [2][3] Company Performance - Juzhi Biotechnology demonstrated strong growth resilience in a sluggish market, achieving a revenue of 3.113 billion yuan in the first half of 2025, a year-on-year increase of 22.52%, and a net profit of 1.182 billion yuan, up 20.23% [4] - The company's main business focuses on professional skincare products and health foods, with professional skincare products accounting for over 99% of its core revenue [4] Brand Performance - The flagship brand, Kefu Mei, generated 2.54 billion yuan in revenue in the first half of 2025, a 22.7% increase, representing 81.7% of total revenue, with key products performing well in major sales events [5] - The Keli Jin brand also showed strong performance with a revenue of 503 million yuan, up 26.9%, and its star product ranked in the top 4 of the Tmall sales list for facial masks [5] Future Outlook - Juzhi Biotechnology plans to continue focusing on its main business, enhancing innovation, strengthening its omnichannel layout, and expanding into medical aesthetics and overseas markets to contribute to the high-quality development of the biological skincare industry [5]

Core Insights - The instant retail sector in China is projected to exceed 1 trillion yuan by 2026 and reach 2 trillion yuan by 2030, driven by the dual forces of digital economy and consumer transformation [1] - JD Fashion's instant delivery service is experiencing explosive growth, becoming a key method for brands to engage in instant retail and for consumers to access trendy products [1] Group 1: Industry Growth and Trends - The Ministry of Commerce's report indicates that the instant retail market is set for significant expansion, with a focus on building a robust ecosystem for high-quality development [1] - JD Fashion's instant delivery service has onboarded over 1,000 merchants by the end of 2025, including major retail brands, and has seen a more than 150% year-on-year increase in store numbers [1] Group 2: Sales Performance - Major sports brands like Nike, Adidas, and Anta have reported over 200% year-on-year growth in sales through JD Fashion's instant delivery service, with some categories like underwear seeing a 500% increase [1] - During the Qixi Festival in 2025, the beauty and skincare category saw a 150% year-on-year increase in sales, with luxury brands experiencing growth rates exceeding 600% [2] Group 3: Seasonal Promotions and Consumer Engagement - JD Fashion's instant delivery service is capitalizing on seasonal events, offering significant discounts and promotions for products like beauty gift sets and sports apparel during holidays [2] - The service aims to address consumer pain points by ensuring product quality and timely delivery, enhancing the overall shopping experience [2]

Core Insights - The instant retail sector is being redefined by "minute-level fulfillment" under the dual drive of digital economy and consumer transformation, with the scale expected to exceed 1 trillion yuan by 2026 and reach 2 trillion yuan by 2030 [1] - Building a robust ecosystem and promoting high-quality development are key topics for the instant retail industry [1] Group 1: Market Growth and Trends - JD Fashion's instant delivery service is set to accelerate its supply layout in core categories such as apparel, sports, and beauty by 2025, leading to explosive growth and becoming a crucial method for brands to reach consumers [1] - By the end of 2025, JD Fashion's instant delivery will have over 1,000 merchants, including major domestic retail giants and sports brands, with a year-on-year increase in store numbers exceeding 150% [1] - The sales volume of brands like Nike, Adidas, and Anta has more than doubled year-on-year, with some categories like underwear seeing a fivefold increase since the beginning of the year [3] Group 2: Seasonal and Promotional Performance - Significant growth in instant consumption demand for holiday gifting has been observed, with JD Fashion's instant delivery service reporting over 150% year-on-year growth in beauty and skincare sales during the Qixi Festival [5] - International beauty brands such as SK-II and Dior saw their sales increase by over six times during this period, with specific products becoming bestsellers [5] - Upcoming promotions for holidays like New Year's Day will feature discounts on popular items, enhancing the consumer experience and addressing gifting needs [5] Group 3: Future Outlook - JD Fashion's instant delivery aims to continue expanding its service and fulfillment capabilities, focusing on consumer pain points such as emergencies, seasonal changes, and gifting [5] - The goal is to ensure product quality and delivery timeliness, making the "anytime, anywhere, instant access" fashion consumption experience a norm [5]